JOP20200044A1 - مثبط انتقائي egfr طافر exon 18 و/أو exon 21 - Google Patents
مثبط انتقائي egfr طافر exon 18 و/أو exon 21Info
- Publication number
- JOP20200044A1 JOP20200044A1 JOP/2020/0044A JOP20200044A JOP20200044A1 JO P20200044 A1 JOP20200044 A1 JO P20200044A1 JO P20200044 A JOP20200044 A JO P20200044A JO P20200044 A1 JOP20200044 A1 JO P20200044A1
- Authority
- JO
- Jordan
- Prior art keywords
- exon
- mutation
- selective inhibitor
- mutant egfr
- egfr selective
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
غير متوفر
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 | ||
| PCT/JP2018/032314 WO2019045036A1 (ja) | 2017-09-01 | 2018-08-31 | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20200044A1 true JOP20200044A1 (ar) | 2020-02-26 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2020/0044A JOP20200044A1 (ar) | 2017-09-01 | 2018-08-31 | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (ar) |
| EP (1) | EP3677266B1 (ar) |
| JP (1) | JP7065103B2 (ar) |
| KR (1) | KR20200044918A (ar) |
| CN (2) | CN117159551A (ar) |
| AU (1) | AU2018325819B2 (ar) |
| BR (1) | BR112020004000A2 (ar) |
| CA (2) | CA3224526A1 (ar) |
| DK (1) | DK3677266T3 (ar) |
| FI (1) | FI3677266T3 (ar) |
| IL (1) | IL272929B1 (ar) |
| JO (1) | JOP20200044A1 (ar) |
| MX (1) | MX2020002296A (ar) |
| PH (1) | PH12020500419A1 (ar) |
| PT (1) | PT3677266T (ar) |
| SG (1) | SG11202001861WA (ar) |
| WO (1) | WO2019045036A1 (ar) |
| ZA (1) | ZA202001445B (ar) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| JOP20200044A1 (ar) | 2017-09-01 | 2020-02-26 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
| SG11202106986VA (en) * | 2018-12-28 | 2021-07-29 | Taiho Pharmaceutical Co Ltd | L718 and/or l792 mutant treatment-resistant egfr inhibitor |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| AU2006227447A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| WO2011004610A1 (ja) | 2009-07-10 | 2011-01-13 | 大鵬薬品工業株式会社 | アザ二環式化合物又はその塩 |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| MX2013007938A (es) | 2011-01-07 | 2013-11-01 | Taiho Pharmaceutical Co Ltd | Compuesto biciclico novedoso o sal del mismo. |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| ES2580530T3 (es) | 2012-02-23 | 2016-08-24 | Taiho Pharmaceutical Co., Ltd. | Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo |
| KR20150119401A (ko) | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
| HUE034807T2 (en) | 2013-08-22 | 2018-02-28 | Taiho Pharmaceutical Co Ltd | New quinoline-substituted compound |
| WO2015175632A1 (en) | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| BR112016029662B1 (pt) | 2014-06-19 | 2023-10-24 | Takeda Pharmaceutical Company Limited | COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| JOP20200044A1 (ar) | 2017-09-01 | 2020-02-26 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 |
-
2018
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 CA CA3224526A patent/CA3224526A1/en active Pending
- 2018-08-31 DK DK18851555.5T patent/DK3677266T3/da active
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja unknown
- 2018-08-31 BR BR112020004000-2A patent/BR112020004000A2/pt unknown
- 2018-08-31 IL IL272929A patent/IL272929B1/en unknown
- 2018-08-31 KR KR1020207008984A patent/KR20200044918A/ko active IP Right Grant
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020112357A (ru) | 2021-10-04 |
| IL272929B1 (en) | 2024-01-01 |
| IL272929A (en) | 2020-04-30 |
| ZA202001445B (en) | 2023-10-25 |
| EP3677266B1 (en) | 2024-01-17 |
| CN111465397A (zh) | 2020-07-28 |
| US11701359B2 (en) | 2023-07-18 |
| CA3224526A1 (en) | 2019-03-07 |
| TW201912160A (zh) | 2019-04-01 |
| DK3677266T3 (da) | 2024-04-22 |
| WO2019045036A1 (ja) | 2019-03-07 |
| FI3677266T3 (fi) | 2024-03-22 |
| EP3677266A1 (en) | 2020-07-08 |
| CA3074418A1 (en) | 2019-03-07 |
| SG11202001861WA (en) | 2020-04-29 |
| AU2018325819B2 (en) | 2024-02-01 |
| RU2020112357A3 (ar) | 2022-02-18 |
| KR20200044918A (ko) | 2020-04-29 |
| MX2020002296A (es) | 2020-09-10 |
| PT3677266T (pt) | 2024-03-04 |
| JPWO2019045036A1 (ja) | 2020-10-15 |
| CA3074418C (en) | 2024-04-23 |
| CN111465397B (zh) | 2023-10-13 |
| US20200253975A1 (en) | 2020-08-13 |
| EP3677266A4 (en) | 2021-05-12 |
| AU2018325819A1 (en) | 2020-03-19 |
| JP7065103B2 (ja) | 2022-05-11 |
| CN117159551A (zh) | 2023-12-05 |
| PH12020500419A1 (en) | 2021-03-01 |
| BR112020004000A2 (pt) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
| JOP20190073A1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| MX2021013661A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos. | |
| MX2021013662A (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. | |
| SG11201907038WA (en) | Quinazoline compound | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| PH12019502197A1 (en) | Macrocyclic compound and uses thereof | |
| TW200628156A (en) | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases | |
| MX2019002108A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| TW200505443A (en) | Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
| MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
| ZA202000354B (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
| MX2017014782A (es) | Metodo para el tratamiento de enfermedad neurologica. | |
| IL283666A (en) | A method for identifying, preventing, reversing and treating neurological diseases | |
| ZA202104679B (en) | L718 and/or l792 mutant treatment-resistant egfr inhibitor | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| IL286649A (en) | The history of quinoline and its use in cancer treatment | |
| MX2022006278A (es) | Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos. | |
| EP3972684A4 (en) | SYSTEMS AND METHODS FOR TREATMENT OF TUMORS BY TARGETED NEUROSTIMULATION | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof |